TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03332693

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Leg weight raising

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Leg weight raising

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Volunteers will not participate in exercise
Study: NCT03093324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 8700
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.
Study: NCT01700621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix vaccine
Description: one 1.0 ml dose of oral rotavirus vaccine at 9 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles-rubella vaccine
Description: one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: measles-rubella vaccine
Description: one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
Study: NCT06160037

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transportation and Developmental Screening
Description: Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy
Description: Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
Study: NCT04663360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse Drug Reaction (ADRe) Profile
Description: ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
Study: NCT02592967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041757 (Cohort 1A and 1B)
Description: JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\] ) and at a higher dose in Cohort 1B (1x10\^9 CFU)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041757 (Cohort 2A and 2B)
Description: JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
Study: NCT02925364

Intervention type: RADIATION
Intervention: magnetic resonance imaging (MRI)
Description: all participants will undergo a functional MRI and an anatomical MRI in a single session

Intervention type: RADIATION
Intervention: magnetic resonance imaging (MRI)
Description: all participants will undergo a functional MRI and an anatomical MRI in a single session
Study: NCT03282838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (fasted)
Description: DFN-15 administered to fasted subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (fed)
Description: DFN-15 administered to fed subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator Celebrex® (fed)
Description: Comparator (Celebrex®) administered to fed subjects
Study: NCT03093506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose rhEpo
Description: 60IU/kg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micro-dose rhEpo
Description: 20IU/kg/week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Saline
Study: NCT04062890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin Pill
Description: Oral Vigabatrin Pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Oral Placebo Pill
Study: NCT03902171

Intervention type: DEVICE
Intervention: Soberlink
Description: Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.

Intervention type: DEVICE
Intervention: Soberlink
Description: Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
Study: NCT02502110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
Study: NCT02412215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with toric Nanoflex IOL implantation
Description: A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoFlex toric Intraocular Lens
Study: NCT04089982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Chantix

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT03611894

Intervention type: OTHER
Intervention: radiological comparison
Description: comparison between clinical and radiological characteristics

Intervention type: OTHER
Intervention: radiological comparison
Description: comparison between clinical and radiological characteristics

Intervention type: OTHER
Intervention: radiological comparison
Description: comparison between clinical and radiological characteristics
Study: NCT02067793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 1 mg
Description: Single intravenous administration of 1 mg into arm on Day 0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous injection into the arm on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 5 mg
Description: Single intravenous injection of 5 mg into the arm on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 10 mg
Description: Single intravenous injection of 10 mg into the arm on Day 0
Study: NCT02994186

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.

Intervention type: OTHER
Intervention: Medical Weight Loss Program
Description: These are patients who will be starting a structured medical weight loss program.
Study: NCT01768858

Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
Study: NCT00677196

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The stonebreaker arm (LMA Stonebreaker)
Description: The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Lithotripsy (Swiss LithoClastR)
Description: Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
Study: NCT02226458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Study: NCT03583606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-EBO-Z
Description: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-EBO-Z
Description: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd3-EBO-Z
Description: Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Multi-Filo Ebola Vaccine
Description: A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL normal saline administered via IM injection into the deltoid.
Study: NCT02164838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Study: NCT00532636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: Mask ventilation in neutral and head extension position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: Mask ventilation in neutral and head extension position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: Mask ventilation in neutral and head extension position
Study: NCT01762748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
Study: NCT04366141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVID-19 barrier box
Description: Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
Study: NCT00866593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Escitalopram
Description: 10mg/d or 20mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innovator Escitalopram
Description: 10mg/d or 20mg/d
Study: NCT01604850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SOF
Description: Placebo to match SOF was administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match RBV
Description: Placebo to match RBV was administered orally twice daily.
Study: NCT05696639

Intervention type: PROCEDURE
Intervention: Aneurysm embolization
Description: All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.

Intervention type: PROCEDURE
Intervention: Aneurysm embolization
Description: All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
Study: NCT02510547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CrossBoss Catheter
Description: Upfront use of the CrossBoss catheter for CTO lesion crossing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade Wire Escalation Strategy
Description: Upfront guidewire escalation strategy for CTO lesion crossing
Study: NCT03006965

Intervention type: DRUG
Intervention: octocog alfa
Description: Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software

Intervention type: DRUG
Intervention: rurioctocog alfa pegol
Description: Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
Study: NCT04900584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Description: Checklist of guideline-based treatment before discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Heart failure education before discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone monitoring
Description: Telephone monitoring after discharge
Study: NCT02680626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Given via transversus abdominis plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Given via transversus abdominis plane block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Given via transversus abdominis plane block
Study: NCT05809765

Intervention type: OTHER
Group type: OTHER
Intervention: 8-week breath training program
Description: The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.

Intervention type: OTHER
Group type: OTHER
Intervention: 8-week breath training program
Description: The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
Study: NCT03157388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Vancomycin and Gentamycin and Meropenem
Description: The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice.
Study: NCT01110447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
Study: NCT04354532

Intervention type: PROCEDURE
Intervention: Laparoscopic Banded Sleeve Gastrectomy
Description: The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
Study: NCT03026270

Intervention type: OTHER
Group type: OTHER
Intervention: Paraffin
Description: The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded

Intervention type: OTHER
Group type: OTHER
Intervention: Paraffin
Description: The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
Study: NCT02788448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVASURE CLOSURE DEVICE
Description: Large hole closure device
Study: NCT01740661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
Study: NCT03806062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: 10 mg domperidone 3 times a day after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: 10 mg domperidone 3 times a day after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: 10 mg domperidone 3 times a day after meals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: He-Ne laser (Bravo TrezaSerie) device
Description: The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: faradic current
Description: faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
Study: NCT04833998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extremecare
Description: The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
Study: NCT03083548

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examinations
Description: Joint assessment of hands and feet, pain sensitization test and functional tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnnaires
Description: Self-reported demographic factors, clinical variables and OA history and symptoms
Study: NCT03618953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-E6E7
Description: Adenovirus vaccine expressing mutant HPV E6 and E7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-E6E7
Description: Adenovirus vaccine expressing mutant HPV E6 and E7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1-E6E7
Description: MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1-E6E7
Description: MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: monoclonal antibody; checkpoint inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: monoclonal antibody; checkpoint inhibitor
Study: NCT01661270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
Study: NCT02457013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Hygh flow nasal canula HFNC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: nasal nCPAP
Study: NCT04590378

Intervention type: OTHER
Intervention: intensive care unit admission ratio
Description: intensive care unit admission ratio

Intervention type: OTHER
Intervention: intensive care unit admission ratio
Description: intensive care unit admission ratio
Study: NCT04638153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: Recifercept
Study: NCT00496444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.